- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07599098
Effects of a Pilates Studio Program on Quality of Life and Functional Capacity of Women Undergoing Breast Cancer Treatment (Cancer)
Effects of a Pilates Studio Program on Quality of Life, Functional Capacity, Pain, Fatigue, Sarcopenia, Flexibility, Strength, Body Composition, Self-Esteem, Anxiety and Depression in Women Undergoing Breast Cancer Treatment
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Andréa D Reis Dra., Teacher
- Número de telefone: 98987220570
- E-mail: andrea.dr@ufma.br
Estude backup de contato
- Nome: Hyrllanny P Santos Hyrllanny Pereira dos Santos, Student
- Número de telefone: 98988359435
- E-mail: hyrllanny.santos@discente.ufma.br
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Women aged 18 or older;
- Being under treatment for breast cancer (chemotherapy, radiotherapy, immunotherapy and/or hormone therapy);
- No previous neurological/musculoskeletal disorders that impede active movement;
- No recent surgeries.
Exclusion Criteria:
- Patients with problems secondary to breast cancer that limit active movement;
- Presence of inflammation or edema in the abdomen, groin, and upper and lower extremities;
- Having another type of cancer;
- Having a cognitive impairment or injury that prevents them from performing physical assessments or completing questionnaires.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Pilates Studio Programming Group
The intervention will consist of 16 weeks of in-person Pilates studio classes, three times a week in the mornings, lasting 60 minutes each, totaling 48 sessions.
|
There will be 16 weeks of intervention, with in-person Pilates studio classes three times a week, lasting 60 minutes each, in the morning, totaling 48 sessions. The classes will follow this order: Warm-up with initial stretches, lasting 10 minutes. This will be followed by the Pilates program lasting 40 minutes, and concluding with a 10-minute relaxation period. Every four weeks there will be a progression in intensity, with modifications to the exercises.
Outros nomes:
|
|
Sem intervenção: Control group
Participants in the Control Group will receive standard care.
They will not participate in the intervention, only answering questionnaires and performing tests during the initial assessment periods, after 4 weeks, 8 weeks, 12 weeks, and after 16 weeks.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain assessment
Prazo: From registration to the end of treatment in 16 weeks
|
Pain will be assessed using the Brief Pain Inventory (BPI), a 10-point pain intensity scale ranging from 0 (no pain) to 10 (worst imaginable pain), developed specifically for patients with cancer-related pain.
In addition, the BPI provides information on how pain interferes with daily functioning in 7 areas: general activity, walking, mood, sleep, work, enjoyment of life, and social activity.
|
From registration to the end of treatment in 16 weeks
|
|
Fatigue
Prazo: From registration to the end of treatment in 16 weeks
|
Fatigue will be measured using the Piper Fatigue Scale (PFS-P).
Fatigue is a relevant symptom for cancer patients, with a greater impact than in the general population.
It is described at all stages of the cancer patient's journey, presenting as physical, emotional, or cognitive exhaustion or weakness, which can interfere with daily function and chemotherapy treatment.
|
From registration to the end of treatment in 16 weeks
|
|
General quality of life evaluation
Prazo: From enrollment to end of treatment in 16 weeks
|
The instrument used to assess Quality of life will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
The questions are using a numerical scale from 0 to 100 for scales.
In the functional and global scales the EORTC-BR 30, the higher scores mean a better quality of life and lower scores mean a worse quality of life.
Unlike, in the symptom scale EORTC-BR 30, the higher scores mean a worse quality of life and lower scores mean a better quality of life.
|
From enrollment to end of treatment in 16 weeks
|
|
Quality of life specifically for breast cancer
Prazo: From registration to the end of treatment in 16 weeks
|
The instrument used to assess Quality of life specifically for breast cancer will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-BR).
The questions are using a numerical scale from 0 to 100 for scales.
In the functional scale the EORTC-BR 23, the higher scores mean a better quality of life and lower scores mean a worse quality of life.
Unlike, in the symptom scale the EORTC-BR 23, the higher scores mean a worse quality of life and lower scores mean a better quality of life.
|
From registration to the end of treatment in 16 weeks
|
|
Sarcopenia
Prazo: From registration to the end of treatment in 16 weeks
|
Sarcopenia assessment will be performed using the SARC-F questionnaire.
The protocol includes five components: strength, assisted gait, rising from a chair, climbing stairs, and falls.
The SARC-F items were selected to reflect changes in health status associated with the consequences of sarcopenia.
SARC-F scale scores range from 0 to 10 (i.e., 0-2 points for each component; 0 = best to 10 = worst) and were dichotomized to represent symptomatic (4+) versus healthy (0-3) status.
Additionally, a modified version of the instrument, the SARC-Calf (SARC-F + CP), which integrates an anthropometric measure into the traditional score, was employed.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity of upper limbs
Prazo: From registration to the end of treatment in 16 weeks
|
The Back Scratch Test is part of the battery of physical fitness tests for older adults and is used to measure the flexibility and range of motion of the shoulder joint (scapular girdle).
The test consists of placing one hand on the same shoulder and the other hand underneath, attempting to touch or overlap the middle fingers of both hands on the back.
The distance between the fingers is measured, where positive values indicate overlap and negative values indicate the distance remaining for touch.
Test scores are classified as: negative (-): If the fingers do not touch (distance between them); zero (0): If the fingers only touch; positive (+): If the fingers overlap.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity of the upper limbs
Prazo: From registration to the end of treatment in 16 weeks
|
The Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire is a validated self-administered instrument for assessing symptoms and functional capacity in individuals with musculoskeletal disorders of the upper limbs. The questionnaire is validated for Brazilian Portuguese and consists of 30 items that assess an individual's ability to perform certain physical activities (21 items), the severity of symptoms such as pain, tingling, and weakness (5 items), and the impact of upper limb function on social life, work, sleep, and self-confidence (4 items). Each item is scored on a scale of 1 to 5. DASH score = ({Sum of responses}/{n} - 1 ) x 25. Where n is the number of questions answered. The score ranges from 0 to 100, where the higher the value, the greater the functional disability. |
From registration to the end of treatment in 16 weeks
|
|
Quality of life specifically for breast cancer
Prazo: From registration to the end of treatment in 16 weeks
|
The instrument used to assess quality of life specifically in cases of breast cancer will be the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-BR).
The questions use a numerical scale from 0 to 100.
On the functional scale of the EORTC-BR-23, higher scores indicate better quality of life and lower scores indicate worse quality of life.
On the symptom scale of the EORTC-BR-23, higher scores indicate worse quality of life and lower scores indicate better quality of life.
|
From registration to the end of treatment in 16 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Functional Capacity: 6-minute walk test
Prazo: From registration to the end of treatment in 16 weeks
|
Functional capacity, or cardiorespiratory fitness, will be assessed using the 6-minute walk test performed in a 10-meter corridor.
The patient will be monitored during the test for safety.
|
From registration to the end of treatment in 16 weeks
|
|
Functional capacity: 6-minute step test
Prazo: From registration to the end of treatment in 16 weeks
|
Functional capacity will be assessed using the 6-minute step test.
The test consists of repeatedly stepping up and down a step with a standardized height between 20 and 30 cm for a continuous period of six minutes, with the total number of cycles or steps completed being recorded at the end of the established time.
The patient will be monitored during the test for safety.
|
From registration to the end of treatment in 16 weeks
|
|
Functional independence
Prazo: From registration to the end of treatment in 16 weeks
|
The Barthel Index is a widely used instrument to assess the degree of functional independence of individuals in performing basic activities of daily living.
Its score ranges from 0 to 100 points, distributed across ten dimensions that encompass tasks related to self-care and mobility.
It is a validated measure for Portuguese, with evidence of reliability and clinical applicability in different contexts of functional assessment.
|
From registration to the end of treatment in 16 weeks
|
|
General Flexibility
Prazo: From registration to the end of treatment, in 16 weeks
|
For flexibility assessment, the Schober test was used, which determines functional flexibility and is more specific to the lumbar region.
It is a test with high specificity compared to the gold standard, radiography.
However, it is a quick and low-cost test, widely used in clinical practice.
The test evaluates lumbar movement restrictions through markings: on the lumbosacral joint (joining the posterior superior iliac spines) and 10 cm above; the distance between these markings is noted in an upright position.
Immediately after, the subject performs a maximum trunk flexion (lower limbs extended), and the evaluator measures the new distance between the points with a measuring tape and records the difference between the marks based on the patient's best reach score in relation to the ground.
|
From registration to the end of treatment, in 16 weeks
|
|
Upper limb strength
Prazo: From registration to the end of treatment, in 16 weeks
|
Measuring handgrip strength using a dynamometer is a simple, objective, practical, and easy-to-use procedure.
Recommended by the American Society of Hand Therapists.
The instruction is to perform a maximum contraction for 3 seconds in each test.
A 30-second rest period is required between each test, and a 2-minute rest period is required between tests for each hand.
|
From registration to the end of treatment, in 16 weeks
|
|
Lower limb strength
Prazo: From registration to the end of treatment, in 16 weeks
|
The 30-Second Chair Stand Test is widely used to assess lower limb strength and muscle endurance in clinical and elderly populations.
The protocol requires the participant to stand from a chair and sit down as many times as possible within 30 seconds, without using their hands.
Performance on this test is a strong predictor of functional autonomy and is directly related to screening for sarcopenia risk.
Classification varies according to age and conditioning achieved during the test, defined as: Disability Risk: >8 repetitions for women are considered predictors of high risk of falls and loss of autonomy; Cutoff Point for Sarcopenia: >15 repetitions is an indicator of reduced muscle quality.
|
From registration to the end of treatment, in 16 weeks
|
|
Muscle Mass
Prazo: From registration to the end of treatment, in 16 weeks.
|
It will be measured using Bioelectrical Impedance Analysis (BIA), a widely used method that estimates muscle mass by measuring the body's resistance and reactance to the passage of a low-intensity electrical current, and is low-cost, easy to apply, and portable.
|
From registration to the end of treatment, in 16 weeks.
|
|
Self-esteem
Prazo: From registration to the end of treatment in 16 weeks
|
To assess self-esteem, the Portuguese version adapted and validated by Hutz of the Rosenberg Self-Esteem Scale will be used.
The total score ranges from 10 to 40 points.
Higher scores indicate better self-esteem and lower scores indicate worse self-esteem.
|
From registration to the end of treatment in 16 weeks
|
|
Anxiety and Depression
Prazo: From registration to the end of treatment, in 16 weeks.
|
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS) questionnaire.
The total score ranges from 0 to 21 points.
The cut-off points adopted will be: an anxiety score of 8 or higher; and a depression score of 9 or higher.
|
From registration to the end of treatment, in 16 weeks.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Andrea Dias Reis, Teacher, Federal University of Maranhão, São Luís, Maranhão, Brazil
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CAAE: 88530425.5.0000.5087
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de mama
-
Sohag UniversityInscrevendo-se por convite
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Istanbul Aydın UniversityConcluído
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
Ensaios clínicos em Pilates Studio Program Group
-
Cairo UniversityConcluídoEsclerose Múltipla Remitente-RecorrenteEgito